Lipids as Targets for Renal Cell Carcinoma Therapy

Tanturovska, Bisera Stepanovska; Manaila, Roxana; Fabbro, Doriano; Huwiler, Andrea

doi:10.3390/ijms24043272

Cited by 5 publications

(1 citation statement)

References 209 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Agonists fingolimod-phosphate [282,716], siponimod [827,1977], BMS-986166 (Partial agonist) [822], BMS-986104 derivative 12 (Biased agonist) [821], BMS-986104 derivative 24 (Biased agonist) [821], etrasimod [325], SAR247799 (Biased agonist) [2062], ST-2191 [2455],…”

Section: Lysophospholipid (S1p) Receptorsmentioning

confidence: 99%

The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors

Alexander,

Christopoulos,

Davenport

et al. 2023

British J Pharmacology

126

View full text Add to dashboard Cite

The Concise Guide to PHARMACOLOGY 2023/24 is the sixth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of approximately 1800 drug targets, and about 6000 interactions with about 3900 ligands. There is an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (https://www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes almost 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point‐in‐time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/bph.16177. G protein‐coupled receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid‐2023, and supersedes data presented in the 2021/22, 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC‐IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.

show abstract

Section: Lysophospholipid (S1p) Receptorsmentioning

confidence: 99%

The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors

Alexander,

Christopoulos,

Davenport

et al. 2023

British J Pharmacology

126

View full text Add to dashboard Cite

show abstract

Integrative analysis of bulk and single‐cell RNA sequencing reveals sphingolipid metabolism and immune landscape in clear cell renal cell carcinoma

Xie,

Han,

Wang

et al. 2024

Environmental Toxicology

View full text Add to dashboard Cite

Clear cell renal cell carcinoma (ccRCC) is characterized by its aggressive behavior and complex molecular heterogeneity, posing significant challenges for treatment and prognostication. This study offers a comprehensive analysis of ccRCC by leveraging both bulk and single‐cell RNA sequencing data, with a specific aim to unravel the complexities of sphingolipid metabolism and the intricate dynamics within the tumor microenvironment (TME). By examining ccRCC samples sourced from public databases, our investigation delves deep into the genetic and transcriptomic landscape of this cancer type. Employing advanced analytical techniques, we have identified pivotal patterns in gene expression and cellular heterogeneity, with a special focus on the roles and interactions of various immune cells within the TME. Significantly, our research has unearthed insights into the dynamics of sphingolipid metabolism in ccRCC, shedding light on its potential implications for tumor progression and strategies for immune evasion. A novel aspect of this study is the development of a risk score model designed to enhance prognostic predictions for ccRCC patients, which is currently pending external validation to ascertain its clinical utility. Despite its contributions, the study is mindful of its limitations, including a reliance on observational data from public sources and a primary focus on RNA sequencing data, which may constrain the depth and generalizability of the findings. The study does not encompass critical aspects, such as protein expression, posttranslational modifications, and comprehensive metabolic profiles. Moreover, its retrospective design underscores the necessity for future prospective studies to solidify these preliminary conclusions. Our findings illuminate the intricate interplay between genetic alterations, sphingolipid metabolism, and immune responses in ccRCC. This research not only enhances our understanding of the molecular foundations of ccRCC but also paves the way for the development of targeted therapies and personalized treatment modalities. The study underlines the importance of cautious interpretation of results and champions ongoing research using diverse methodologies to thoroughly comprehend and effectively combat this formidable cancer type.

show abstract

Multi-sequence MRI-based radiomics model to preoperatively predict the WHO/ISUP grade of clear Cell Renal Cell Carcinoma: a two-center study

Chen,

Su,

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Lipids as Targets for Renal Cell Carcinoma Therapy

Cited by 5 publications

References 209 publications

The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors

The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors

Integrative analysis of bulk and single‐cell RNA sequencing reveals sphingolipid metabolism and immune landscape in clear cell renal cell carcinoma

Multi-sequence MRI-based radiomics model to preoperatively predict the WHO/ISUP grade of clear Cell Renal Cell Carcinoma: a two-center study

Contact Info

Product

Resources

About